Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia

Trial Profile

A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 15 Oct 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sucroferric oxyhydroxide (Primary)
  • Indications Hyperphosphataemia
  • Focus Adverse reactions; Registrational
  • Sponsors Kissei Pharmaceutical
  • Most Recent Events

    • 30 Sep 2015 According to Kissei Pharmaceutical media release, new drug application for sucroferric oxyhydroxide for treatment of hyperphosphatemia has been approved by the Ministry of Health, Labour and Welfare in Japan.
    • 19 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 09 Jun 2014 New trial record
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top